AKESO(HK:09926) Jin Rong Jie·2025-07-21 13:59Group 1 - The core index of the CSI Hong Kong Stock Connect Innovative Drug Index (931250) experienced a decline of 1.42%, closing at 1114.48 points with a trading volume of 16.63 billion yuan [1] - Over the past month, the index has increased by 22.12%, by 65.37% over the last three months, and has risen 94.38% year-to-date [1] - The index comprises 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect [1] Group 2 - The top ten weighted companies in the index include: CanSino Biologics (10.0%), Innovent Biologics (9.88%), BeiGene (8.97%), WuXi Biologics (8.93%), China Biologic Products (7.69%), CSPC Pharmaceutical Group (7.19%), 3SBio (5.66%), Hansoh Pharmaceutical (4.23%), WuXi AppTec (3.5%), and Kelun-Biotech (3.05%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - In terms of industry composition, the index's sample holdings consist of 40.89% in drug formulations, 40.00% in other biopharmaceuticals, 18.70% in pharmaceutical and biotechnology services, and 0.41% in vaccines [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Special circumstances may lead to temporary adjustments to the index, such as delisting of samples or corporate actions like mergers and acquisitions [2]